Evidence map›Paper›PMID 26367466›Full record

ArticleToxicology letters2015

Cytotoxicity of HBD3 for dendritic cells, normal human epidermal keratinocytes, hTERT keratinocytes, and primary oral gingival epithelial keratinocytes in cell culture conditions.

Nattawut Leelakanok, Carol L Fischer, Amber M Bates, Janet M Guthmiller, Georgia K Johnson, Aliasger K Salem, Kim A Brogden, Nicole K Brogden

Open access · greenAbstract read
In one paragraph

Article in Toxicology letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Nattawut LeelakanokDivision of Pharmaceutics and Translational Therapeutics, Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, The University of Iowa, Iowa City, IA 52242, USA. Electronic address: nattawut-leelakanok@uiowa.edu.
Carol L FischerDows Institute for Dental Research, College of Dentistry, The University of Iowa, Iowa City, IA 52242, USA. Electronic address: carol-bratt@uiowa.edu.
Amber M BatesDows Institute for Dental Research, College of Dentistry, The University of Iowa, Iowa City, IA 52242, USA. Electronic address: amber-bates@uiowa.edu.
Janet M GuthmillerCollege of Dentistry, The University of Nebraska Medical Center, Lincoln, NE 68583, USA. Electronic address: janet.guthmiller@unmc.edu.
Georgia K JohnsonDepartment of Periodontics, College of Dentistry, The University of Iowa, Iowa City, IA 52242, USA. Electronic address: georgia-johnson@uiowa.edu.
Aliasger K SalemDivision of Pharmaceutics and Translational Therapeutics, Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, The University of Iowa, Iowa City, IA 52242, USA. Electronic address: aliasger-salem@uiowa.edu.
Kim A BrogdenDows Institute for Dental Research, College of Dentistry, The University of Iowa, Iowa City, IA 52242, USA; Department of Periodontics, College of Dentistry, The University of Iowa, Iowa City, IA 52242, USA. Electronic address: kim-brogden@uiowa.edu.
Nicole K BrogdenDivision of Pharmaceutics and Translational Therapeutics, Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, The University of Iowa, Iowa City, IA 52242, USA. Electronic address: nicole-brogden@uiowa.edu.
University of Iowa · USTranslational Therapeutics (United States) · USUniversity of Nebraska Medical Center · US

Funding

Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Brandi Janssen · 1990 to 2026
$40.5M
University of Iowa Institutional Training Program in Oral Health ResearchT90DE023520 · NIDCR · UNIVERSITY OF IOWA · PI STEVEN M. LEVY · 2013 to 2026
$5.6M
Defensin-induced Adaptive Immunity to HagBR01DE014390 · NIDCR · UNIVERSITY OF IOWA · PI BROGDEN, KIM A · 2003 to 2014
$3.4M
University of Iowa Institutional Training Program in Oral Health ResearchR90DE024296 · NIDCR · UNIVERSITY OF IOWA · PI STEVEN M. LEVY · 2013 to 2026
$1.8M
NIDCR NIH HHS R01 DE014390NIDCR NIH HHS R90 DE024296NIDCR NIH HHS T90 DE02350NIDCR NIH HHS T90 DE023520NIEHS NIH HHS P30 ES005605
6 · The paper itself

Abstract

Human β-defensin 3 (HBD3) is a prominent host defense peptide. In our recent work, we observed that HBD3 modulates pro-inflammatory agonist-induced chemokine and cytokine responses in human myeloid dendritic cells (DCs), often at 20.0 μM concentrations. Since HBD3 can be cytotoxic in some circumstances, it is necessary to assess its cytotoxicity for DCs, normal human epidermal keratinocytes (NHEKs), human telomerase reverse transcriptase (hTERT) keratinocytes, and primary oral gingival epithelial (GE) keratinocytes in different cell culture conditions. Cells, in serum free media with resazurin and in complete media with 10% fetal bovine serum and resazurin, were incubated with 5, 10, 20, and 40 μM HBD3. Cytotoxicity was determined by measuring metabolic conversion of resazurin to resorufin. The lethal dose 50 (LD50, mean μM±Std Err) values were determined from the median fluorescent intensities of test concentrations compared to live and killed cell controls. The LD50 value range of HBD3 was 18.2-35.9 μM in serum-free media for DCs, NHEKs, hTERT keratinocytes, and GE keratinocytes, and >40.0 μM in complete media. Thus, HBD3 was cytotoxic at higher concentrations, which must be considered in future studies of HBD3-modulated chemokine and cytokine responses in vitro.

Indexed as

beta-DefensinsCell LineCells, CulturedCell SurvivalCulture Media, Serum-FreeDendritic CellsDose-Response Relationship, DrugEpithelial CellsGingivaHumansKeratinocytesLethal Dose 50Time Factorsbeta-DefensinsCulture Media, Serum-FreeDEFB103A protein, humanCytotoxicityDefensinsDendritic cellsEpidermal KeratinocytesGingival epithelial GE keratinocytesHBD3hTERT Keratinocytes

Identifiers

PMID26367466
PMCPMC4600674
OpenAlexW1655198019

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.